Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02955459 · ClinicalTrials.gov registry record · Phase 1
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
A Phase 1 study, sponsored by Venatorx Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT02955459 is a Phase 1 study that has completed, run by Venatorx Pharmaceuticals. The registered enrollment target is 84 participants.
The verdict
NCT02955459, a Phase 1 study, has completed, sponsored by Venatorx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2 subjects will receive VNRX-5133 for 7 days.
Interventions
- DRUG Placebo
- DRUG VNRX-5133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02955459
The ClinicalTrials.gov registry entry for NCT02955459 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Venatorx Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02955459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02955459 about?
NCT02955459 is a clinical study titled "VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers". This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2 subjects will receive ...
What is the current status of trial NCT02955459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2016-11. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02955459?
The interventions under investigation include: Placebo (DRUG), VNRX-5133 (DRUG).
Who is sponsoring clinical trial NCT02955459?
This trial is sponsored by Venatorx Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.